The progression of a cancer from the initiating cancer stem cell (CSC) to clinical significance, and ultimately to recurrence after treatment failure, is the culmination of a continuously evolving reciprocal interaction between the CSC and the "stem cell niche". The hypothesis of this proposal is that androgen deprivation perturbs the critical role of the prostate endothelial cell in regulation of the androgenic milieu of the prostate tissue microenvironment, and in regulation of the stem cell "niche", facilitating/accelerating the emergence of castration-recurrent prostate cancer To validate the hypothesis, the following Specific Aims are proposed.
Aim 1 will characterize the role of endothelial cell caveolae in transcytosis of circulating androgens across the endothelial cell barrier, in endocytosis of circulating androgens resulting in AR-transactivation of genes associated with endothelial cell homeostasis and signaling, and in "non-genomic signaling" mediated through cell surface receptors for circulating androgens.
Aim 2 will determine if androgen-deprivation induced killing of prostate endothelial cells results in transient, or irreversible, perturbation of the endothelial cells of the prostate microvasculature resulting in dysregulation of the tissue androgenic milieu (characterized using LC/MS/MS) and in creation/unmasking of unique, targetable "epitopes" or "vascular addresses" (characterized using phage peptide-display technology).
Aim 3 will identify the effect of androgen deprivation on genes and gene pathways that are differentially expressed in prostate CSCs compared to adult stem cells (ASCs), identify the cell surface "epitope" fingerprint of prostate ASCs/CSCs, and determine if perturbation of the stem cell "niche" results in epigenetically-modulated dysregulation of the HNF-4n transcription network in prostate CSCs. The data and reagents generated in Aims 1-3 will support the studies of Aim 4 focused on development of novel approaches for utilizing androgen-deprivation to enable prostate-specific therapies by validating that: androgen deprivation exposes the ASC/CSC to targeted therapy;transcytosis of circulating androgens can be inhibited without perturbation of endothelial cell homeostasis;and endothelial cell initiated signaling to ASCs/CSCs can be reprogrammed to induce the stem cell to exit the "niche" and commit to differentiation.

Public Health Relevance

Androgen deprivation therapy (ADT) has been the standard-of-care for advanced prostate cancer (CaP) for 60 years, but rarely is curative and has significant side-effects. This project proposes 2 complementary using strengths of ADT. First, transient ADT will expose the inaccessible CaP stem cell to short-term targeted therapy. Second, movement of circulating androgens across the micro-vascular barrier will be blocked by inhibiting endothelial cell-mediated androgen transport, a prostate-specific ADT, to prevent access of circulating adrenal androgens to CaP to minimize systemic collateral side effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA077739-15
Application #
8650264
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
15
Fiscal Year
2014
Total Cost
$387,762
Indirect Cost
$33,756
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mohler, James L (2014) Concept and viability of androgen annihilation for advanced prostate cancer. Cancer 120:2628-37
Titus, Mark A; Li, Yun; Kozyreva, Olga G et al. (2014) 5*-reductase type 3 enzyme in benign and malignant prostate. Prostate 74:235-49
Wilson, Elizabeth M (2014) More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer. Asian J Androl 16:99-100
Kim, Won; Zhang, Li; Wilton, John H et al. (2014) Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res 20:6269-76
Tan, Jiann-an; Bai, Suxia; Grossman, Gail et al. (2014) Mechanism of androgen receptor corepression by CK*BP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Mol Cell Endocrinol 382:302-13
Su, Shifeng; Minges, John T; Grossman, Gail et al. (2013) Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins. J Biol Chem 288:24809-24
James, Smitha R; Cedeno, Carlos D; Sharma, Ashok et al. (2013) DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics 8:849-63
Fiandalo, Michael V; Wu, Wenjie; Mohler, James L (2013) The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets 14:420-40
Chhipa, Rishi Raj; Halim, Danny; Cheng, Jinrong et al. (2013) The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate 73:1483-94
Wu, Yue; Godoy, Alejandro; Azzouni, Faris et al. (2013) Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5*-reductase inhibitors. Prostate 73:1470-82

Showing the most recent 10 out of 81 publications